Monday, 9 April 2012

Azactam for Injection 1g or 2g





1. Name Of The Medicinal Product



Azactam 1g Powder for Solution for Injection or Infusion, vial



Azactam 2g Powder for Solution for Injection or Infusion, vial


2. Qualitative And Quantitative Composition



Each vial contains 1g aztreonam.



Each vial contains 2g aztreonam.



3. Pharmaceutical Form



Powder for solution for injection or infusion.



4. Clinical Particulars



4.1 Therapeutic Indications



The treatment of the following infections caused by susceptible aerobic Gram-negative micro-organisms:



Urinary tract infections: including pyelonephritis and cystitis (initial and recurrent) and asymptomatic bacteriuria, including those due to pathogens resistant to the aminoglycosides, cephalosporins or penicillins.



Gonorrhoea: acute uncomplicated urogenital or anorectal infections due to beta-lactamase producing or non-producing strains of N. gonorrhoeae.



Lower respiratory tract infections: including pneumonia, bronchitis and lung infections in patients with cystic fibrosis.



Bacteraemia/septicaemia.



Meningitis caused by Haemophilus influenzae or Neisseria meningitidis. Since Azactam provides only Gram negative cover, it should not be given alone as initial blind therapy, but may be used with an antibiotic active against Gram positive organisms until the results of sensitivity tests are known.



Bone and joint infections.



Skin and soft tissue infections: including those associated with postoperative wounds, ulcers and burns.



Intra-abdominal infections: peritonitis.



Gynaecological infections: pelvic inflammatory disease, endometritis and pelvic cellulitis.



Azactam is indicated for adjunctive therapy to surgery in the management of infections caused by susceptible organisms, including abscesses, infections complicating hollow viscus perforations, cutaneous infections and infections of serous surfaces.



Bacteriological studies to determine the causative organism(s) and their sensitivity to aztreonam should be performed. Therapy may be instituted prior to receiving the results of sensitivity tests.



In patients at risk of infections due to non-susceptible pathogens, additional antibiotic therapy should be initiated concurrently with Azactam to provide broad-spectrum coverage before identification and susceptibility testing results of the causative organism(s) are known. Based on these results, appropriate antibiotic therapy should be continued.



Patients with serious Pseudomonas infections may benefit from concurrent use of Azactam and an aminoglycoside because of their synergistic action. If such concurrent therapy is considered in these patients, susceptibility tests should be performed in vitro to determine the activity in combination. The usual monitoring of serum levels and renal function during aminoglycoside therapy applies.



4.2 Posology And Method Of Administration



Intramuscular or intravenous injection, or intravenous infusion.



Adults:



The dose range of Azactam is 1 to 8g daily in equally divided doses. The usual dose is 3 to 4g daily. The maximum recommended dose is 8g daily. The dosage and route of administration should be determined by the susceptibility of the causative organisms, severity of infection and the condition of the patient.



Dosage Guide: Adults (see table below)












































Type of Infection1




Dosage




Frequency



(hours)




Route


 


Urinary tract infections




500 mg or 1 g




8 or 12




IM or IV


 


Gonorrhoea / cystitis




1 g




single dose




IM


 


Cystic fibrosis




2 g




6 - 8




IV


 


Moderately severe systemic infections




1 g or 2 g




8 or 12




IM or IV


 


Severe systemic or life-threatening infections




2 g




6 or 8




IM or IV


 


Other infections




either



or




1 g



2 g




8



12




IM or IV



IV




1 Because of the serious nature of infections due to Pseudomonas aeruginosa, a dose of 2g every 6 or 8 hours is recommended, at least for initial therapy in systemic infections caused by this organism.


    


The intravenous route is recommended for patients requiring single doses greater than 1g, or those with bacterial septicaemia, localised parenchymal abscess (e.g. intra-abdominal abscess), peritonitis, meningitis or other severe systemic or life-threatening infections.



Elderly:



Renal status is a major determinant of dosage in the elderly; these patients in particular may have diminished renal function. Serum creatinine may not be an accurate determinant of renal status. Therefore, as with all antibiotics eliminated by the kidneys, estimates of creatinine clearance should be obtained, and appropriate dosage modifications made if necessary.



Elderly patients normally have a creatinine clearance in excess of 30ml/min and therefore would receive the normal recommended dose. If renal function is below this level, the dosage schedule should be adjusted (see Renal Impairment).



Renal Impairment:



Prolonged serum levels of aztreonam may occur in patients with transient or persistent renal insufficiency. Therefore, after an initial usual dose, the dosage of aztreonam should be halved in patients with estimated creatinine clearances between 10 and 30 mL/min/1.73 m2.



In patients with severe renal failure (creatinine clearance less than 10 mL/min/1.73 m2), such as those supported by hemodialysis, the usual dose should be given initially. The maintenance dose should be one-fourth of the usual initial dose given at the usual fixed interval of 6, 8 or 12 hours. For serious or life-threatening infections, in addition to the maintenance doses, one-eighth of the initial dose should be given after each hemodialysis session.



Paediatric:



The usual dosage for patients older than one week is 30mg/kg/dose every 6 or 8 hours. For severe infections in patients 2 years of age or older, 50mg/kg/dose every 6 or 8 hours is recommended. The recommended dose for all patients in the treatment of infections due to P. aeruginosa is 50 mg/kg every six to eight hours.



The maximum daily paediatric dose should not exceed the maximum recommended dose for adults.



Dosage information is not yet available for new-borns less than 1 week old.



Reconstitution



Azactam for Injection 1g or 2 g Vial are supplied in 15ml vials.



Upon the addition of the diluent the contents should be shaken immediately and vigorously. Vials of reconstituted Azactam are not intended for multi-dose use, and any unused solution from a single dose must be discarded. Depending on the type and amount of diluent, the pH ranges from 4.5 to 7.5, and the colour may vary from colourless to light straw-yellow, which may develop a slight pink tint on standing; however this does not affect the potency.



For intramuscular injection: For each gram of aztreonam add at least 3ml Water for Injections Ph. Eur. or 0.9% Sodium Chloride Injection B.P. and shake well.










Single Dose Vial Size




Volume of Diluent to be Added




0.5g




1.5ml




1.0g




3.0ml



Azactam is given by deep injection into a large muscle mass, such as the upper quadrant of the gluteus maximus or the lateral part of the thigh.



For intravenous injection: To the contents of the vial add 6 to 10ml of Water for Injections Ph. Eur. and shake well. Slowly inject directly into the vein over a period of 3 to 5 minutes.



For intravenous infusion:



Vials: For each gram of aztreonam add at least 3ml of Water for Injections Ph. Eur. and shake well.



Dilute this initial solution with an appropriate infusion solution to a final concentration less than 2% w/v (at least 50ml solution per gram of aztreonam). The infusion should be administered over 20-60 minutes.



Appropriate infusion solutions include:



0.9% Sodium Chloride Injection B.P.



5% Glucose Intravenous Infusion B.P.



5% or 10% Mannitol Intravenous Infusion B.P.



Sodium Lactate Intravenous Infusion B.P.



0.9%, 0.45% or 0.2% Sodium Chloride and 5% Glucose Intravenous Infusion B.P.



Compound Sodium Chloride Injection B.P.C. 1959 (Ringer's Solution for Injection)



Compound Sodium Lactate Intravenous Infusion B.P. (Hartmann's Solution for Injection).



A volume control administration set may be used to deliver the initial solution of Azactam into a compatible infusion solution being administered. With use of a Y-tube administration set, careful attention should be given to the calculated volume of Azactam solution required so that the entire dose will be infused.



Reconstitution:



Intravenous infusion solutions of Azactam for Injection prepared with 0.9% Sodium Chloride Injection B.P. or 5% Glucose Intravenous B.P., in PVC or glass containers, to which clindamycin phosphate, gentamicin sulphate, tobramycin sulphate, or cephazolin sodium have been added at concentrations usually used clinically, are stable for up to 24 hours in a refrigerator (2-8°C). Ampicillin sodium admixtures with aztreonam in 0.9% Sodium Chloride Injection B.P. are stable for 24 hours in a refrigerator (2-8°C); stability in 5% Glucose Intravenous Infusion B.P. is eight hours under refrigeration.



If aztreonam and metronidazole are to be used together, they should be administered separately as a cherry red colour has been observed after storage of solutions containing combinations of the two products.



4.3 Contraindications



Patients with a known hypersensitivity to aztreonam and L-arginine.



Aztreonam is contraindicated in pregnancy. Aztreonam crosses the placenta and enters the foetal circulation.



4.4 Special Warnings And Precautions For Use



Allergic reactions



Antibiotics, like other drugs, should be given with caution to any patients with a history of allergic reaction to structurally related compounds. If an allergic reactions occurs, discontinue the drug and institute supportive treatments as approprite. Serious hypersensitivity reactions may require epinephrine and other emergency measures. Specific studies have not shown significant cross-reactivity between Azactam and antibodies to penicillins or cephalosporins. The incidence of hypersensitivity to Azactam in clinical trials has been low but caution should be exercised in patients with a history of hypersensitivity to beta-lactam antibiotics until further experience is gained.



Renal/hepatic impairment



In patients with impaired hepatic or renal function, appropriate monitoring is recommended during therapy.



Serious blood/skin disorders



Serious blood disorders (incl. pancytopenia) and skin disorders (incl. toxic epidermal necrolysis) have been reported with the use of aztreonam. In case of serious hemogram and skin changes, it is recommended to stop aztreonam.



Convulsions



Convulsions have rarely been reported during treatment with beta-lactams, including aztreonam (see section 4.8).



Clostridium difficile associated diarrhoea



Clostridium difficile associated diarrhoea (CDAD) has been reported with use of nearly all antibacterial agents, including Azactam, and may range in severity from mild diarrhoea to fatal colitis. CDAD must be considered in all patients who present with diarrhoea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued. Medication that inhibits intestinal peristalsis should not be given.



Concurrent therapy with other antimicrobial agents and Azactam is recommended as initial therapy in patients who are at risk of having an infection due to pathogens that are not susceptible to aztreonam.



As with other antibiotics, in the treatment of acute pulmonary exacerbations in patients with cystic fibrosis, while clinical improvement is usually noted, lasting bacterial eradications may not be achieved.



Overgrowth of non-susceptible organisms



Therapy with Azactam may result in overgrowth of non-susceptible organisms, including gram-positive organisms and fungi. Should superinfection occur during therapy, appropriate measures should be taken. In comparative studies, the number of patients treated for superinfections was similar to that of the control drugs used.



Prolongation of prothrombin time / increased activity of oral anticoagulants



Prolongation of prothrombin time has been reported rarely in patients receiving aztreonam. Additionally, numerous cases of increased activity of oral anticoagulants have been reported in patients receiving antibiotics, including beta-lactams. Severe infection or inflammation, and the age and general condition of the patient appear to be risk factors. Appropriate monitoring should be undertaken when anticoagulants are prescribed concomitantly. Adjustments in the dose of oral anticoagulants may be necessary to maintain the desired level of anticoagulation (see section 4.5 and 4.8).



Concomitant use with aminoglycosides



If an aminoglycoside is used concurrently with aztreonam, especially if high dosages of the former are used or if therapy is prolonged, renal function should be monitored because of the potential nephrotoxicity and ototoxicity of aminoglycoside antibiotics.



Paediatric population



Data on safety and effectiveness in neonates younger than one week are limited; use in this population needs to be carefully assessed.



Arginine



Aztreonam for injection contains arginine. Studies in low birth weight infants have demonstrated that arginine administered in the aztreonam formulation may result in increases in serum arginine, insulin, and indirect bilirubin. The consequences of exposure to this amino acid during treatment of neonates have not been fully ascertained.



Interference with serological testing



A positive direct or indirect Coombs test may develop during treatment with aztreonam.



4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction



Concomitant administration of probenecid or furosemide and aztreonam cause clinically insignificant increases in the serum levels of aztreonam.



Due to the induction of beta-lactamases, certain antibiotics (eg, cefoxitin, imipenem) have been found to cause antagonism with many beta-lactams, including aztreonam, for certain gram-negative aerobes, such as Enterobacter species and Pseudomonas species.



Appropriate monitoring should be undertaken when anticoagulants are prescribed concomitantly. Adjustments in the dose of oral anticoagulants may be necessary to maintain the desired level of anticoagulation (see section 4.4 and 4.8).



Single-dose pharmacokinetic studies have not shown any significant interaction between aztreonam and gentamicin, cephradine, clindamycin or metronidazole.



Unlike broad spectrum antibiotics, aztreonam produces no effects on the normal anaerobic intestinal flora. No disulfiram-like reactions with alcohol ingestion have been reported.



4.6 Pregnancy And Lactation



Aztreonam is contraindicated in pregnancy. Aztreonam crosses the placenta and enters the foetal circulation.



There are no adequate and well-controlled studies in pregnant women. Studies in pregnant rats and rabbits, with daily doses up to 15 and 5 times the maximum recommended human dose respectively, revealed no evidence of embryo- or fetotoxicity or teratogenicity. Because animal reproduction studies are not always predictive of human response, aztreonam should be used during pregnancy only if clearly needed.



Aztreonam is excreted in breast milk in concentrations that are less than 1% of those in simultaneously obtained maternal serum. Lactating mothers should refrain from breast feeding during the course of therapy.



4.7 Effects On Ability To Drive And Use Machines



No studies on the effects on the ability to drive and use machines have been performed.



4.8 Undesirable Effects



The list of undesirable effects shown below is presented by system organ class, MedDRA preferred term, and frequency.
















































































































System Organ Class




Common






Uncommon






Rare






Very Rare



< 1/10 000




Frequency not known (cannot be estimated from available data)




Infections and infestations




 




 




Vaginitis, vaginal candidiasis



 

 


Blood and lymphatic system disorders




 




 




Pancytopeniaa, thrombocytopenia, thrombocythaemias, leukocytosis, neutropenia, eosinophilia, anaemia, prothrombin time prolonged, activated partial thromboplastin time prolonged, Coombs test positivea



 

 


Immune system disorders




 




 



 

 


Anaphylactic reaction




Psychiatric disorders




 




 




Confusional state, insomnia



 

 


Nervous system disorders




 




 




Convulsionsa, paresthesia, dizziness, headache



 


Dysgeusia




Eye disorders




 




 




Diplopia



 

 


Ear and labyrinth disorders




 




 




Vertigo, tinnitus



 

 


Vascular disorders




 




 




Hypotension, haemorrhage



 


Phlebitis, thrombophlebitis, flushing




Respiratory, thoracic and mediastinal disorders




 




 




Wheezing, dyspnoea, sneezing, nasal congestion



 


Bronchospasm




Gastrointestinal disorders




 




 




Gastro intestinal haemorrhage, pseudomembranous colitisa, breath odour



 


Abdominal pains, mouth ulceration, nausea, vomiting, diarrhoea, altered taste




Hepato-biliary disorders




 




 




Hepatitis, jaundice



 


Transaminases increased*, blood alkaline phosphatase increased*




Skin and subcutaneous tissue disorders




 




 



 

 


Toxic epidermal necrolysisa, angioedema, erythema multiforme, dermatitis exfoliative, hyperhidrosis, petechiae, purpura, urticaria, rash, pruritus




Renal and urinary disorders




 




Blood creatinine increased



 

 

 


Musculoskeletal, connective tissue and bone disorders




 




 




Myalgia



 

 


Reproductive system and breast disorders




 




 




Breast tenderness



 

 


General disorders and administration site conditions




 




 




Chest pain, pyrexia, asthenia, malaise



 


Injection site discomfort, weakness, sweating, muscle aches, fever, transient increases in serum creatinine




Investigations




 




 




Electrocardiogram change



 

 


*Usually reversing during therapy and without overt signs or symptoms of hepatobiliary dysfunction.



a See section 4.4.



4.9 Overdose



There have been no reported cases of overdosage. If necessary, aztreonam may be cleared from the serum by hemodialysis and/or peritoneal dialysis. Aztreonam has been shown to be cleared from the serum by continuous arteriovenous hemofiltration.



5. Pharmacological Properties



5.1 Pharmacodynamic Properties



Aztreonam is a monocyclic beta-lactam antibiotic with potent bactericidal activity against a wide spectrum of Gram-negative aerobic pathogens.



Unlike the majority of beta-lactam antibiotics, it is not an inducer in vitro of beta-lactamase activity. Aztreonam is usually active in vitro against those resistant aerobic organisms whose beta-lactamases hydrolyse other antibiotics.



5.2 Pharmacokinetic Properties



Single 30-minute i.v. infusions of 0.5g, 1.0g and 2.0g in healthy volunteers produced peak serum levels of 54, 90 and 204 mg/l, and single 3-minute i.v. injections of the same doses produced peak levels of 58, 125 and 242 mg/l. Peak levels of aztreonam are achieved at about one hour after i.m. administration. After identical single i.m. or i.v. doses, the serum concentrations are comparable at 1 hour (1.5 hours from the start of i.v. infusion), with similar slopes of serum concentrations thereafter.



The serum half-life of aztreonam averaged 1.7 hours in subjects with normal renal function, independent of the dose and route. In healthy subjects 60-70% of a single i.m. or i.v. dose was recovered in the urine by 8 hours, and urinary excretion was essentially complete by 12 hours.



5.3 Preclinical Safety Data



Aztreonam was well tolerated in a comprehensive series of preclinical toxicity and safety studies.



6. Pharmaceutical Particulars



6.1 List Of Excipients



L-arginine (780mg per g of aztreonam).



6.2 Incompatibilities



Azactam should not be physically mixed with any other drug, antibiotic or diluent, except those listed in the Posology and Method of Administration section under Reconstitution for Intravenous infusion.



With intermittent infusion of Azactam and another drug via a common delivery tube, the tube should be flushed before and after delivery of Azactam with any appropriate infusion solution compatible with both drug solutions. The drugs should not be delivered simultaneously.



6.3 Shelf Life








(a) Product unopened:




36 months




(b) Reconstituted product:




24 hours (2-8°C)



6.4 Special Precautions For Storage



(a) Storage before reconstitution:



Do not store above 25°C.



(b) Stability after reconstitution:



Store at 2-8°C for not more than 24 hours.



Discard any unused solution.



6.5 Nature And Contents Of Container








1g glass vials:




pack of 1 x 15 ml




2g glass vials:




pack of 1 x 15 ml



6.6 Special Precautions For Disposal And Other Handling



Any content of product remaining after use should be discarded.



7. Marketing Authorisation Holder



E.R. Squibb & Sons Limited



Uxbridge Business Park



Sanderson Road



Uxbridge



Middlesex



UB8 1DH



8. Marketing Authorisation Number(S)








Azactam 1g vial:




PL 0034/0251




Azactam 2g vial:




PL 0034/0252



9. Date Of First Authorisation/Renewal Of The Authorisation



15th October 1986 / 22nd November 1991 / 13th August 1998



10. Date Of Revision Of The Text



14 June 2011




Monday, 2 April 2012

Sterapred


Generic Name: Prednisone
Class: Adrenals
ATC Class: H02AB07
VA Class: HS051
CAS Number: 53-03-2

Introduction

Synthetic glucocorticoid; minimal mineralocorticoid activity.b


Uses for Sterapred


Treatment of a wide variety of diseases and conditions; used principally for glucocorticoid effects as an anti-inflammatory and immunosuppressant agent and for its effects on blood and lymphatic systems in the palliative treatment of various diseases.c


Adrenocortical Insufficiency


Corticosteroids are administered in physiologic dosages to replace deficient endogenous hormones in patients with adrenocortical insufficiency.c


Because production of both mineralocorticoids and glucocorticoids is deficient in adrenocortical insufficiency, hydrocortisone or cortisone (in conjunction with liberal salt intake) usually is the corticosteroid of choice for replacement therapy.a c d


Usually inadequate alone for adrenocortical insufficiency because of minimal mineralocorticoid activity.b


If prednisone is used for adrenocortical insufficiency, a mineralocorticoid (e.g., fludrocortisone) must also be administered, particularly in infants.a c d


Adrenogenital Syndrome


Lifelong glucocorticoid treatment of adrenogenital syndrome (e.g., congenital adrenal hyperplasia).c


In salt-losing forms, cortisone or hydrocortisone is preferred in conjunction with liberal salt intake; concomitant use of a mineralocorticoid may be necessary until the patient is at least 5–7 years of age.c


For long-term therapy after early childhood, a glucocorticoid alone usually is sufficient.c


In hypertensive forms, a “short-acting” glucocorticoid with minimal mineralocorticoid activity (e.g., methylprednisolone, prednisone) is preferred.c Avoid long-acting glucocorticoids (e.g., dexamethasone) because of tendency toward overdosage and growth retardation.c


Hypercalcemia


Treatment of hypercalcemia associated with malignancy.a c d


Usually ameliorates hypercalcemia associated with bone involvement in multiple myeloma.c


Treatment of hypercalcemia associated with sarcoidosis†.c


Treatment of hypercalcemia associated with vitamin D intoxication†.c


Not effective for hypercalcemia caused by hyperparathyroidism†.c


Thyroiditis


Treatment of granulomatous (subacute, nonsuppurative) thyroiditis.a c d


Anti-inflammatory actions relieves fever, acute thyroid pain, and swelling.c


May reduce orbital edema in endocrine exophthalmos (thyroid ophthalmopathy).c


Usually reserved for palliative therapy in severely ill patients unresponsive to salicylates and thyroid hormones.c


Rheumatic Disorders and Collagen Diseases


Short-term palliative treatment of acute episodes or exacerbations and systemic complications of rheumatic disorders (e.g., rheumatoid arthritis, juvenile arthritis, psoriatic arthritis, acute gouty arthritis, posttraumatic osteoarthritis, synovitis of osteoarthritis, epicondylitis, acute nonspecific tenosynovitis, ankylosing spondylitis, Reiter syndrome†, rheumatic fever† [especially with carditis]) and collagen diseases (e.g., acute rheumatic carditis, systemic lupus erythematosus, systemic dermatomyositis† [polymyositis], polyarteritis nodosa†, vasculitis†) refractory to more conservative measures.a c d e


Relieves inflammation and suppresses symptoms but not disease progression.c


Rarely indicated as maintenance therapy.c


May be used as maintenance therapy (e.g., in rheumatoid arthritis, acute gouty arthritis, systemic lupus erythematosus, acute rheumatic carditis) as part of a total treatment program in selected patients when more conservative therapies have proven ineffective.a c d


Glucocorticoid withdrawal is extremely difficult if used for maintenance; relapse and recurrence usually occur with drug discontinuance.c


Controls acute manifestations of rheumatic carditis more rapidly than salicylates and may be life-saving; cannot prevent valvular damage and no better than salicylates for long-term treatment.c


Adjunctively for severe systemic complications of Wegener’s granulomatosis†, but cytotoxic therapy is the treatment of choice.c


Primary treatment to control symptoms and prevent severe, often life-threatening complications of systemic lupus erythematosus, systemic dermatomyositis (polymyositis), polyarteritis nodosa†, relapsing polychondritis, polymyalgia rheumatica, Sjogren's syndrome, giant-cell (temporal) arteritis†, certain cases of vasculitis, or mixed connective tissue disease syndrome†.c e High dosage may be required for acute situations; after a response has been obtained, drug must often be continued for long periods at low dosage.c


Polymyositis† associated with malignancy and childhood dermatomyositis may not respond well.c


Rarely indicated in psoriatic arthritis, diffuse scleroderma† (progressive systemic sclerosis), or osteoarthritis; risks outweigh benefits.c


Dermatologic Diseases


Treatment of pemphigus and pemphigoid†, bullous dermatitis herpetiformis, severe erythema multiforme (Stevens-Johnson syndrome), exfoliative dermatitis, severe eczema†, cutaneous sarcoidosis†, mycosis fungoides, and severe seborrheic dermatitis.a c d e


Usually reserved for acute exacerbations unresponsive to conservative therapy.c


Early initiation of systemic glucocorticoid therapy may be life-saving in pemphigus vulgaris and pemphigoid†, and high or massive doses may be required.c


For control of severe or incapacitating allergic conditions (e.g., contact dermatitis, atopic dermatitis) refractory to adequate trials of conventional treatment.a d e


Chronic skin disorders seldom an indication for systemic glucocorticoids.c


Used for severe psoriasis but rarely indicated systemically;c d if used, exacerbation may occur when the drug is withdrawn or dosage is decreased.c


Rarely indicated systemically for alopecia areata†, alopecia totalis†, or alopecia universalis†.c May stimulate hair growth, but hair loss returns when the drug is discontinued.c


Allergic Conditions


For control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment; for control of acute manifestations, including angioedema†, serum sickness, allergic symptoms of trichinosis†, urticarial transfusion reactions, drug hypersensitivity reactions, and severe seasonal or perennial rhinitis.a c d e


Systemic therapy usually reserved for acute conditions and severe exacerbations.c


For acute conditions, usually used in high dosage and with other therapies (e.g., antihistamines, sympathomimetics).c


Reserve prolonged treatment for patients with chronic, disabling allergic conditions unresponsive to more conservative therapy and for those in whom risks of long-term glucocorticoid therapy are justified.c f


Ocular Disorders


To suppress a variety of allergic and nonpyogenic ocular inflammations.c


To reduce scarring in ocular injuries†.c


For the treatment of severe acute and chronic allergic and inflammatory processes involving the eye and adnexa, including allergic corneal marginal ulcers, herpes zoster ophthalmicus, anterior segment inflammation, diffuse posterior uveitis and choroiditis, sympathetic ophthalmia, allergic conjunctivitis, keratitis, chorioretinitis, optic neuritis, iritis and iridocyclitis.


Acute optic neuritis optimally treated with initial high-dose IV (e.g., methylprednisolone) therapy followed by chronic oral corticosteroid therapy. Aids in recovery of vision and slows progression to clinically definite multiple sclerosis. In a randomized, placebo-controlled trial, oral prednisone monotherapy did not improve the rate of vision recovery and was associated with an increased risk of new episodes of optic neuritis in either eye.


Less severe allergic and inflammatory allergic conditions of the eye are treated with topical ophthalmic corticosteroids.j


Systemically in stubborn cases of anterior segment eye disease and when deeper ocular structures are involved.c


Oral Disorders†


Has been used for oral disorders (i.e., desquamative gingivitis, recurrent aphthous stomatitis) that are unresponsive to topical therapy.e Confirm diagnosis of desquamative gingivitis via immunofluorescence biopsy assay.e


Asthma


Adjunctively for moderate to severe exacerbations of asthma and for maintenance in persistent asthma.c g


Corticosteroids used systemically (oral or IV) for treatment of moderate to severe acute exacerbations of asthma (oral prednisone usually preferred); speeds resolution of airflow obstruction and reduces rate of relapse.j


Because onset of effects is delayed, do not use alone for emergency treatment.c


Early systemic glucocorticoid therapy particularly important for asthma exacerbations in infants and children.j


Orally as an adjunct to other therapy to speed resolution of all but the mildest exacerbations of asthma when response to a short-acting inhaled β2-agonist is not prompt or sustained after 1 hour or in those who have a history of severe exacerbations.c


Oral glucocorticoids with minimal mineralocorticoid activity and relatively short half-life (e.g., prednisone, prednisolone, methylprednisolone) are preferred.


In hospital management of an acute asthma exacerbation, should use systemic adjunctive glucocorticoids if response to oral inhalation therapy is not immediate, if oral corticosteroids were used as self-medication prior to hospitalization, or if the episode is severe.c


For severe persistent asthma once initial control is achieved, high dosages of inhaled corticosteroids are preferable to oral glucocorticoids for maintenance because inhaled corticosteroids have fewer systemic effects.


Maintenance therapy with low doses of an orally inhaled corticosteroid is preferred treatment for adults and children with mild persistent asthmac (i.e., patients with daytime symptoms of asthma more than twice weekly but less than once daily, and nocturnal symptoms of asthma more than twice per month).b


COPD


For severe exacerbations of COPD†, a short (e.g., 1–2 weeks) course of oral glucocorticoids can be added to existing therapy.


Much less dramatic effects in stable COPD than in asthma, and the role of glucocorticoids is limited to very specific indications.m


Sarcoidosis


Management of symptomatic sarcoidosis.a c d f


Systemic glucocorticoids are indicated for hypercalcemia; ocular, CNS, glandular, myocardial, or severe pulmonary involvement; or severe skin lesions unresponsive to intralesional injections of glucocorticoids.c


Advanced Pulmonary and Extrapulmonary Tuberculosis


Used systemically as adjunctive therapy with effective antimycobacterial agents (e.g., streptomycin, isoniazid) to suppress manifestations related to the host’s inflammatory response to the bacillus (Mycobacterium tuberculosis) and ameliorate complications in severe pulmonary or extrapulmonary (disseminated) tuberculosis.a


In advanced pulmonary tuberculosis, adjunctive glucocorticoid therapy may enhance short-term resolution of disease manifestations (e.g., clinical and radiographic abnormalities).


In certain forms of extrapulmonary disease (e.g., meningitis, pericarditis), also may reduce mortality.


In moderate to severe tuberculous meningitis, systemic adjunctive glucocorticoids may reduce sequelae (e.g., intellectual impairment) and/or improve survival. Used concurrently with appropriate antituberculous chemotherapy in the treatment of tuberculous meningitis with subarachnoid block or impending block.a d f Speeds resolution of abnormal CSF parameters (e.g., elevated intracranial pressure, basal exudate, CNS tuberculomas).


In acute tuberculous pericarditis, systemic adjunctive glucocorticoid therapy rapidly reduces the size of pericardial effusions and the need for drainage procedures and decreases mortality (probably through control of hemodynamically threatening effusion).


In tuberculous pleurisy, hastens the resolution of pain, dyspnea, and fever.


Lipid Pneumonitis†


Promotes the breakdown or dissolution of pulmonary lesions and eliminates sputum lipids.c


Pneumocystis jiroveci (Pnemocystis carinii) Pneumonia†


Used adjunctively with appropriate anti-infective therapy in the management of moderate to severe Pneumocystis jiroveci (formerly Pneumocystis carinii) pneumonia in patients with acquired immunodeficiency syndrome (AIDS)† to decreases the likelihood of deterioration of oxygenation, respiratory failure, and/or death.


Loeffler’s Syndrome


Symptomatic relief of acute manifestations of symptomatic Loeffler’s syndrome not manageable by other means.f


Berylliosis


Symptomatic relief of acute manifestations of berylliosis.d f


Aspiration Pneumonitis


Symptomatic relief of acute manifestations of aspiration pneumonitis.d f


Anthrax


Adjunct to anti-infective therapy in the treatment of anthrax† in an attempt to ameliorate toxin-mediated effects associated with Bacillus anthracis infections.


Used for cutaneous anthrax† if there are signs of systemic involvement or extensive edema involving the neck and thoracic region. Has been used for anthrax meningitis† and inhalational anthrax† that occurs as the result of exposure to anthrax spores in the context of biologic warfare or bioterrorism if extensive edema, respiratory compromise, or meningitis is present.


Hematologic Disorders


Management of acquired (autoimmune) hemolytic anemia, idiopathic thrombocytopenic purpura (ITP), secondary thrombocytopenia, erythroblastopenia, congenital (erythroid) hypoplastic anemia, or hemolysis†.a d e


High or even massive dosages decrease bleeding tendencies and normalize blood counts; does not affect the course or duration of hematologic disorders.c


Glucocorticoids, immune globulin IV (IGIV), or splenectomy are first-line therapies for moderate to severe ITP, depending on the extent of bleeding involved.


May not affect or prevent renal complications in Henoch-Schoenlein purpura.c


Insufficient evidence of effectiveness in aplastic anemia in children, but widely used.c


Pericarditis


To reduce the pain, fever, and inflammation of pericarditis†, including that associated with MI.c


Glucocorticoids can provide effective symptomatic relief, but aspirin considered the treatment of choice for postmyocardial infarction pericarditis because of greater evidence establishing benefit.


Important to distinguish between pain caused by pericarditis and that caused by ischemia since management will differ.


Consider possibility that cardiac rupture may account for recurrent pain since use of glucocorticoids may be a risk factor in its development.


Glucocorticoids may cause thinning of developing scar and myocardial rupture.


Management of tuberculous pericarditis. (See Advanced Pulmonary and Extrapulmonary Tuberculosis under Uses.)


GI Diseases


Short-term palliative therapy for acute exacerbations and systemic complications of ulcerative colitis, regional enteritis, or celiac disease†.a c d e Low dosages of glucocorticoids, in conjunction with other supportive therapy, may occasionally be useful for patients unresponsive to usual therapy for chronic conditions.c


Do not use if a probability of impending perforation, abscess, or other pyogenic infection.f


Crohn’s Disease


Management of mildly to moderately active and moderately to severely active Crohn’s disease.f


Some experts state that conventional glucocorticoids should not be used for the management of mildly to moderately active disease because of their high incidence of adverse effects, and their use should be reserved for patients with moderately to severely active disease.


Parenteral glucocorticoids recommended for patients with severe fulminant Crohn’s disease†. Once patients respond to parenteral therapy, they should gradually be switched to an equivalent regimen of an oral glucocorticoid.


Glucocorticoids should not be used for maintenance therapy of Crohn’s disease because they usually do not prevent relapses and the drugs may produce severe adverse reactions with long-term administration.


Glucocorticoids have been used in the management of moderately to severely active Crohn’s disease and in mild esophageal or gastroduodenal Crohn’s disease† in pediatric patients.


Neoplastic Diseases


Alone or as a component of various chemotherapeutic regimens in the palliative treatment of neoplastic diseases of the lymphatic system (e.g., leukemias and lymphomas in adults and acute leukemias in children).a c d f


In adults, acute lymphocytic (lymphoblastic) leukemia, chronic lymphocytic leukemia, and Hodgkin’s disease respond well to combination regimens that include a glucocorticoid (usually prednisone or prednisolone).c Acute myeloblastic leukemia, lymphosarcoma, and the blast crisis of chronic myelocytic leukemia may fail to respond or may relapse upon discontinuance of therapy.c


Treatment of breast cancer†e ; glucocorticoids alone not as effective as other agents (e.g., cytotoxic agents, hormones, antiestrogens) and should be reserved for unresponsive disease.c


Glucocorticoids alone or as a component of various combination chemotherapeutic regimens for palliative treatment of advanced, symptomatic (i.e., painful) hormone-refractory prostate cancer†.


Has been used in Waldenstrom's macroglobulinemia†, fever associated with neoplasms†, and multiple myeloma†.e


Cerebral Malaria†


Glucocorticoids are not effective and can have detrimental effects in the management of cerebral malaria† caused by Plasmodium falciparum; no longer recommended for this condition.c


Liver Disease†


In patients with subacute hepatic necrosis† and chronic active hepatitis†,e high-dose glucocorticoids can decrease serum bilirubin, ascites, and mortality rate.c In nonalcoholic cirrhosis† in women,e the drugs increase survival rate in the absence of ascites, but not when ascites is present.c May decrease mortality rate in patients with alcoholic cirrhosis with hepatic encephalopathy†, but should not be used in less seriously ill patients.c


Multiple Sclerosis


Glucocorticoids are drugs of choice for the management of acute relapses of multiple sclerosis.a d Have replaced corticotropin as the therapy of choice because of a more rapid onset of action, more consistent effects, and fewer adverse effects.


Anti-inflammatory and immunomodulating effects accelerate neurologic recovery by restoring the blood-brain barrier, reducing edema, and possibly improving axonal conduction.


Shortens the duration of relapse and accelerates recovery; remains to be established whether the overall degree of recovery improves or the long-term course is altered.


Myasthenia Gravis


Management of myasthenia gravis†, usually when there is an inadequate response to anticholinesterase therapy.e


Organ Transplants†


Used in massive dosages with or without other immunosuppressive drugs to prevent rejection of transplanted organs†.c e


Incidence of secondary infections is high with immunosuppressive drugs; limit to clinicians experienced in their use.c


Trichinosis


Treatment of trichinosis with neurologic or myocardial involvement.a d f


Nephrotic Syndrome and Lupus Nephritis


Treatment of idiopathic nephrotic syndrome without uremia.a d f


Can induce diuresis and remission of proteinuria in nephrotic syndromea c d f secondary to primary renal disease, especially when there is minimal renal histologic change.c


Treatment of lupus nephritis.a d f


Sterapred Dosage and Administration


General



  • Dosage depends on the condition being treated and the patient response.a b f



Alternate-day Therapy



  • Alternate-day therapy, in which a single dose (twice the usual daily dosage) is administered every other morning, is the dosage regimen of choice for long-term oral glucocorticoid treatment of most conditions.a c This regimen provides relief of symptoms while minimizing adrenal suppression, protein catabolism, and other adverse effects.a c




  • If alternate-day therapy is preferred, only use a “short-acting” glucocorticoid that suppresses the HPA axis <1.5 days after a single oral dose (e.g., prednisone, prednisolone, methylprednisolone).c




  • Some conditions (e.g., rheumatoid arthritis, ulcerative colitis) require daily glucocorticoid therapy because symptoms of the underlying disease cannot be controlled by alternate-day therapy.c



Discontinuance of Therapy



  • A steroid withdrawal syndrome consisting of lethargy, fever, myalgia can develop following abrupt discontinuance.c Symptoms often occur without evidence of adrenal insufficiency (while plasma glucocorticoid concentrations were still high but were falling rapidly).c




  • If used for only brief periods (a few days) in emergency situations, may reduce and discontinue dosage quite rapidly.c




  • Very gradually withdraw systemic glucocorticoids until recovery of HPA-axis function occurs following long-term therapy with pharmacologic dosages.c d f (See Adrenocortical Insufficiency under Cautions.)




  • Exercise caution when transferring from systemic glucocorticoid to oral or nasal inhalation corticosteroid therapy.c




  • Many methods of slow withdrawal or “tapering” have been described.c




  • In one suggested regimen, decrease by 2.5–5 mg every 3–7 days until the physiologic dose (5 mg) is reached.c




  • Other recommendations state that decrements usually should not exceed 2.5 mg every 1–2 weeks.c




  • When physiologic dosage is reached, single 20-mg oral morning doses of hydrocortisone can be substituted for whatever glucocorticoid the patient was receiving.c After 2–4 weeks, may decrease hydrocortisone dosage by 2.5 mg every week until a single morning dosage of 10 mg daily reached.c




  • For certain acute allergic conditions (e.g., contact dermatitis such as poison ivy) or acute exacerbations of chronic allergic conditions, glucocorticoids may be administered short term (e.g., for 6 days).c Administer a high dose on the first day of therapy, then withdraw therapy by tapering the dosage over several days.c (See Allergic Conditions under Dosage and Administration.)



Administration


Oral Administration


Administered orally as tablets, solution, or solution concentrate; also has been administered as an extemporaneously prepared suspension.b May dilute oral concentrate in juice or other flavored diluent or in semisolid food (e.g., applesauce) prior to administration.b


To prepare an extemporaneous suspension containing prednisone 10 mg/mL, mix 5 g of prednisone as tablets with 200 mL of 0.1% sodium benzoate solution.b Add 100 mL of an aqueous suspension containing 3% tragacanth, 3% acacia, and 0.1% sodium benzoate and stir the mixture until homogeneous.b Dilute to 500 mL with a mixture of 67% simple syrup and 33% cherry syrup to a final concentration of 10 mg/mL.b


May prepare 4 L of the tragacanth-acacia suspension in a container that can be closed for vigorous agitation.b Initially, dissolve 4 g of sodium benzoate in 2 L of purified water.b Add 120 g of powdered tragacanth and 120 g of acacia in that order and shake the container vigorously.b Add additional water gradually over 24–48 hours with agitation at regular intervals until a volume of 4 L and a smooth suspension results.b To mask the odor, may add 1 mL of anise oil.b


Dosage


After a satisfactory response is obtained, decrease dosage in small decrements to the lowest level that maintains an adequate clinical response, and discontinue the drug as soon as possible.b f


Monitor patients continually for signs that indicate dosage adjustment is necessary, such as remissions or exacerbations of the disease and stress (surgery, infection, trauma).b f


High dosages may be required for acute situations of certain rheumatic disorders and collagen diseases.c After a response has been obtained, drug often must be continued for long periods at low dosage.c


High or massive dosages may be required in the treatment of pemphigus, exfoliative dermatitis, bullous dermatitis herpetiformis, severe erythema multiforme, or mycosis fungoides.c Early initiation of systemic glucocorticoid therapy may be life-saving in pemphigus vulgaris.c Reduce dosage gradually to the lowest effective level, but discontinuance may not be possible.c


Pediatric Patients


Base pediatric dosage on severity of the disease and patient response rather than on strict adherence to dosage indicated by age, body weight, or body surface area.b


Usual Dosage

Oral

0.14–2 mg/kg daily or 4–60 mg/m2 daily in 4 divided doses.b


Pneumocystis jiroveci (Pneumocystis carinii) Pneumonia

Oral

Adolescents >13 years of age with moderate to severe Pneumocystis jiroveci (formerly Pneumocystis carinii) pneumonia and acquired immunodeficiency syndrome† (AIDS): 40 mg twice daily for 5 days, followed by 40 mg once daily for 5 days, and then 20 mg once daily for 11 days (or until completion of the anti-infective regimen) currently is recommended. Initiate glucocorticoid therapy within 24–72 hours of initial antipneumocystis therapy. Consult published protocols and the most current clinical guidelines.


Allergic Conditions

Oral

For certain conditions (e.g., contact dermatitis, including poison ivy), 30 mg (6 tablets) for the first day, which is then tapered by 5 mg daily until 21 tablets have been administered (see Table 1).b

















Table 1. Tapered Dosage Schedule

Day



Dosage Schedule



Day 1



Administer 10 mg twice daily (before breakfast and at bedtime) and 5 mg twice daily (after lunch and dinner).b



Day 2



Administer 5 mg 3 times daily (before breakfast, after lunch, and after dinner) and 10 mg at bedtime.b



Day 3



Administer 5 mg 4 times daily (before breakfast, after lunch, after dinner, and at bedtime).b



Day 4



Administer 5 mg 3 times daily (before breakfast, after lunch, and at bedtime).b



Day 5



Administer 5 mg twice daily (before breakfast and at bedtime).b



Day 6



Administer 5 mg before breakfast.b


Adults


Usual Dosage

Oral

Initially, 5–60 mg daily, depending on the disease being treated, usually in 2–4 divided doses.b f


Pneumocystis jiroveci (Pneumocystis carinii) Pneumonia

Oral

Adults with moderate to severe Pneumocystis jiroveci (formerly Pneumocystis carinii) pneumonia and acquired immunodeficiency syndrome† (AIDS): 40 mg twice daily for 5 days, followed by 40 mg once daily for 5 days, and then 20 mg once daily for 11 days (or until completion of the anti-infective regimen) currently is recommended. Initiate within 24–72 hours of initial antipneumocystis therapy. Consult published protocols and the most current clinical guidelines.


Allergic Conditions

Oral

For certain conditions (e.g., contact dermatitis, including poison ivy), 30 mg (6 tablets) for the first day, which is then tapered by 5 mg daily until 21 tablets have been administered (see Table 2).b

















Tapered Dosage Schedule

Day



Dosage Schedule



Day 1



Administer 10 mg twice daily (before breakfast and at bedtime) and 5 mg twice daily (after lunch and dinner)b



Day 2



Administer 5 mg 3 times daily (before breakfast, after lunch, and after dinner) and 10 mg at bedtimeb



Day 3



Administer 5 mg 4 times daily (before breakfast, after lunch, after dinner, and at bedtime)b



Day 4



Administer 5 mg 3 times daily (before breakfast, after lunch, and at bedtime)b



Day 5



Administer 5 mg twice daily (before breakfast and at bedtime)b



Day 6



Administer 5 mg before breakfastb


Advanced Pulmonary or Extrapulmonary Tuberculosis

Oral

For severe systemic and respiratory complications of advanced pulmonary tuberculosis: 40–60 mg daily, tapered over 4–8 weeks.101 102


Tuberculous meningitis: 1 mg/kg daily for 30 days, followed by gradual tapering of the dosage over a period of weeks, has been suggested.102


Tuberculous pericarditis: 60 mg daily tapered over 6–12 weeks.


Tuberculous pleurisy: 20–40 mg daily tapered over 4–8 weeks.


Mediastinal lymphadenopathy associated with primary intrathoracic tuberculosis: 2–5 mg/kg per day (or equivalent), with dosage reduction to 1 mg/kg per day over the first week and tapered over the next 5 weeks.


Multiple Sclerosis

Oral

For acute exacerbations, the manufacturer recommends 200 mg daily for 1 week followed by 80 mg every other day for 1 month.a Alternatively, 60 mg daily tapering over 12 days following IV methylprednisolone (1 g daily for 3–5 days) has been used.


Optic Neuritis

Oral

1 mg/kg daily for 11 days following IV methylprednisolone therapy (1 g daily for 3 days).


Cautions for Sterapred


Contraindications



  • Known hypersensitivity to prednisone, any ingredient in the respective formulation, or any other corticosteroid.a c d f




  • Systemic fungal infections.a d f




  • Concurrent administration of live or live, attenuated vaccines in patients receiving immunosuppressive doses of corticosteroids.a d f (See Specific Drugs and Laboratory Tests under Interactions.)



Warnings/Precautions


Warnings


Adrenocortical Insufficiency

When given in supraphysiologic doses for prolonged periods, glucocorticoids may cause decreased secretion of endogenous corticosteroids by suppressing pituitary release of corticotropin (secondary adrenocortical insufficiency).c


The degree and duration of adrenocortical insufficiency is highly variable among patients and depends on the dose, frequency and time of administration, and duration of glucocorticoid therapy.c


Acute adrenal insufficiency (even death) may occur if the drugs are withdrawn abruptly or if patients are transferred from systemic glucocorticoid therapy to local (e.g., inhalation) therapy.c


Withdraw prednisone very gradually following long-term therapy with pharmacologic dosages.c (See Discontinuance of Therapy under Dosage and Administration.)


Adrenal suppression may persist up to 12 months in patients who receive large dosages for prolonged periods.c


Until recovery occurs, may develop signs and symptoms of adrenal insufficiency if subjected to stress (e.g., infection, surgery, trauma, illness) and may require replacement therapy.a c d f Since mineralocorticoid secretion may be impaired, sodium chloride and/or a mineralocorticoid also should be administered.c d f


If the disease flares up during withdrawal, may need to increase dosage and follow with a more gradual withdrawal.c


Immunosuppression

Increased susceptibility to infections secondary to glucocorticoid-induced immunosuppression.d Certain infections (e.g., varicella [chickenpox], measles) can have a more serious or even fatal outcome in such patients.d (See Increased Susceptibility to Infection under Cautions.)


Administration of live virus vaccines, including smallpox, is contraindicated in patients receiving immunosuppressive dosages of glucocorticoids.d In addition, if inactivated viral or bacterial vaccines are administered to such patients, expected serum antibody response may not be obtained.a c d The USPHS Advisory Committee on Immunization Practices (ACIP) and American Academy of Family Physicians (AAFP) state that administration of live virus vaccines usually is not contraindicated in patients receiving corticosteroid therapy under the following circumstances:



  • short-term (<2 weeks) therapy




  • low to moderate dosage




  • long-term alternate-day treatment with short-acting preparations




  • maintenance physiologic dosages (replacement therapy)




  • topical, ophthalmic, intra-articular, bursol, or intratendon administration



Increased Susceptibility to Infection

Glucocorticoids, especially in large doses, increase susceptibility to and mask symptoms of infection.d


Infections with any pathogen, including viral, bacterial, fungal, protozoan, or helminthic infections in any organ system, may be associated with glucocorticoids alone or in combination with other immunosuppressive agents.d


Infections may be mild, but they can be severe or fatal, and localized infections may disseminate.


Do not use, except in life-threatening situations, in patients with viral infections or bacterial infections not controlled by anti-infectives.c


Some infections (e.g., varicella [chickenpox], measles) can have a more serious or even fatal outcome, particularly in children.d


Children and any adult who are not likely to have been exposed to varicella or measles should avoid exposure to these infections while receiving glucocorticoids.d


If exposure to varicella or measles occurs in susceptible patients, treat appropriately (e.g., varicella zoster immune globulin [VZIG], immune globulin [IG], acyclovir).d


Fatal outcome (e.g., in those developing hemorrhagic varicella) may not always be avoided even if appropriate therapy is initiated aggressively.


Immunosuppression may result in activation of latent infection or exacerbation of intercurrent infections (e.g., those caused by Candida, Mycobacterium, Toxoplasma, Strongyloides, Pneumocystis, Cryptococcus, Nocardia, Ameba).


Use with great care in patients with known or suspected Strongyloides (threadworm) infection.d Immunosuppression may lead to Strongyloides hyperinfection and dissemination with widespread larval migration, often accompanied by severe enterocolitis and potentially fatal gram-negative septicemia.


Not effective and can have detrimental effects in the management of cerebral malaria.c


Can reactivate tuberculosis.c Include chemoprophylaxis in patients with a history of active tuberculosis undergoing prolonged glucocorticoid therapy.c d Observe closely for evidence of reactivation.d f Restrict use in active tuberculosis to those with fulminating or disseminated tuberculosis in which glucocorticoids are used in conjunction with appropriate antimycobacterial chemotherapy.d f


Can reactivate latent amebiasis.c Exclude possible amebiasis in any patient who has been in the tropics or who has unexplained diarrhea prior to initiating therapy.c


Musculoskeletal Effects

Muscle wasting, muscle pain or weakness, delayed wound healing, and atrophy of the protein matrix of the bone resulting in osteoporosis, vertebral compression fractures, aseptic necrosis of femoral or humeral heads, or pathologic fractures of long bones are manifestations of protein catabolism that may occur during prolonged therapy with glucocorticoids.c These adverse effects may be especially serious in geriatric or debilitated patients.c A high protein diet may help to prevent adverse effects associated with protein catabolism.c


An acute, generalized myopathy can occur with the use of high doses of glucocorticoids, particularly in patients with disorders of neuromuscular transmission (e.g., myasthenia gravis) or in patients receiving concomitant therapy with neuromuscular blocking agents (e.g., pancuronium). Use with caution in patients with myasthenia gravis.f


Tendon rupture, particularly of the Achilles tendon.


Osteoporosis and related fractures are one of the most serious adverse effects of long-term glucocorticoid therapy. The American College of Rheumatology (ACR) currently considers patients receiving or planning to receive at least 5 mg of prednisone daily for 3 months or longer to be at risk for bone loss.


To minimize the risk of glucocorticoid-induced bone loss, should use the smallest possible effective dosage and duration and use topical and inhaled preparations whenever possible. Obtain baseline measurement of bone mineral density (BMD) at the lumbar spine and/or hip when initiating long-term (e.g., exceeding 6 months) glucocorticoid therapy and initiate appropriate preventive therapy. May repeat longitudinal measurements as often as every 6 months to detect possible bone loss. Less frequent (e.g., annually) follow-up probably is sufficient in patients who are receiving therapy to prevent bone loss.


Before initiating glucocorticoid therapy in postmenopausal women, consider that they are especially prone to osteoporosis.c


Skeletal wasting is most rapid during the initial 6 months of therapy, and trabecular bone is affected to a greater degree than is cortical bone.


Withdraw glucocorticoids if osteoporosis develops, unless their use is life-saving.c


Calcium and vitamin D supplementation, bisphosphonate (e.g., alendronate, risedronate), and a weight-bearing exercise program that maintains muscle mass are suitable first-line therapies aimed at reducing the risk of adverse bone effects.


Calcitonin may be considered as second-line therapy for patients who refuse or do not tolerate bisphosphonate therapy or for whom the drugs are contraindicated.


Fluid and Electrolyte Disturbances

Sodium retention with resultant edema, potassium loss, and elevation of blood pressure may occur, but is less common with prednisone than with average or large doses of cortisone or hydrocortisone.d Risk is increased with high-dose synthetic glucocorticoids for prolonged periods.c d Edema and CHF (in susceptible patients) may occur.c


Dietary salt restriction is advisable and potassium supplementation may be necessary.c d


Increased calciu

Thursday, 29 March 2012

Actemra


Pronunciation: TOE-si-LIZ-oo-mab
Generic Name: Tocilizumab
Brand Name: Actemra

Patients who use Actemra have an increased risk of developing serious and sometimes fatal infections, including tuberculosis (TB), fungal infection, and other types of infection. Most patients who developed these infections were also taking medicine that suppressed their immune system (eg, corticosteroids, methotrexate).


Patients should receive a TB skin test before using Actemra. Patients who test positive for TB should begin treatment for TB before starting Actemra. All patients should also be monitored for signs of TB while using Actemra even if their TB test is negative.


Contact your doctor immediately if you develop signs of TB or any other type of infection (eg, persistent cough; muscle weakness; unexplained weight loss; fever, chills, or persistent sore throat; shortness of breath; unusual tiredness; warm, red, or painful skin or sores; increased or painful urination; severe or persistent diarrhea; blood in the mucus).





Actemra is used for:

Treating moderate to severe rheumatoid arthritis (RA) in certain patients. It is also used to treat systemic juvenile idiopathic arthritis (SJIA) in children 2 years and older. It may be used alone or in combination with other medicine. It may also be used for other conditions as determined by your doctor.


Actemra is an interleukin-6 (IL-6) receptor blocker. It works by blocking a substance (IL-6) in the body that contributes to inflammation.


Do NOT use Actemra if:


  • you are allergic to any ingredient in Actemra

  • you have a severe infection (eg, sepsis) or any other active infection

  • you have active liver problems

  • you are using abatacept, anakinra, an anti-CD20 monoclonal antibody (eg, rituximab), or a tumor necrosis factor (TNF) blocker (eg, adalimumab)

Contact your doctor or health care provider right away if any of these apply to you.



Before using Actemra:


Some medical conditions may interact with Actemra. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:


  • if you are pregnant, planning to become pregnant, or are breast-feeding

  • if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement

  • if you have allergies to medicines, foods, or other substances

  • if you have low blood platelet or neutrophil levels; a history of hepatitis B infection or other liver problems; stomach or bowel problems (eg, diverticulitis, pain, bleeding, perforation, inflammation, ulcer); high cholesterol; high blood pressure; diabetes; kidney problems; cancer; or numbness, tingling, or other nervous system problems (eg, multiple sclerosis [MS], Guillain-Barré syndrome)

  • if you have an infection, open cuts or sores on your body, flu-like symptoms or other signs of infection (eg, fever; chills; cough; warm, red, or painful skin), shingles, or are using medicine to treat an infection

  • if you have a history of an infection that keeps coming back, TB infection, or a positive TB skin test

  • if you have ever lived in or traveled to an area where TB is common, or if you have come into close contact with a person with active TB

  • if you have ever lived or traveled to certain parts of the country (eg, Ohio or Mississippi river valleys, the Southwest) where certain types of fungal infections (eg, histoplasmosis, coccidioidomycosis, blastomycosis) are common. Check with your doctor if you are not sure if you have lived in an area where these infections are common

  • if you have HIV, a weakened immune system, or you take medicine that may weaken your immune system (eg, cyclosporine)

  • if you have recently received or are scheduled to receive a vaccine, or are using another medicine to treat RA

  • if you will be having surgery or a medical procedure

Some MEDICINES MAY INTERACT with Actemra. Tell your health care provider if you are taking any other medicines, especially any of the following:


  • Abatacept, anakinra, an anti-CD20 monoclonal antibody (eg, rituximab), corticosteroids (eg, prednisone), methotrexate, or TNF blockers (eg, adalimumab) because the risk of serious infection may be increased

  • Medicines that may harm the liver (eg, acetaminophen, methotrexate, ketoconazole, isoniazid, certain medicines for HIV infection) because the risk of liver side effects may be increased. Ask your doctor if you are unsure if any of your medicines might harm the liver

  • Nonsteroidal anti-inflammatory drugs (NSAIDs) (eg, ibuprofen) because the risk of severe stomach problems may be increased

  • Cyclosporine, HMG-CoA reductase inhibitors (eg, atorvastatin), oral contraceptives (birth control pills), theophylline, or warfarin because their effectiveness may be decreased by Actemra

This may not be a complete list of all interactions that may occur. Ask your health care provider if Actemra may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.


How to use Actemra:


Use Actemra as directed by your doctor. Check the label on the medicine for exact dosing instructions.


  • Actemra comes with an extra patient information sheet called a Medication Guide. Read it carefully. Read it again each time you get Actemra refilled.

  • Actemra is usually given as an injection at your doctor's office, hospital, or clinic.

  • Do not use Actemra if it contains particles, is cloudy or discolored, or if the vial is cracked or damaged.

  • Keep this product, as well as syringes and needles, out of the reach of children and pets. Do not reuse needles, syringes, or other materials. Ask your health care provider how to dispose of these materials after use. Follow all local rules for disposal.

  • If you miss a dose of Actemra, contact your doctor.

Ask your health care provider any questions you may have about how to use Actemra.



Important safety information:


  • Actemra may cause dizziness. This effect may be worse if you take it with alcohol or certain medicines. Use Actemra with caution. Do not drive or perform other possibly unsafe tasks until you know how you react to it.

  • Do NOT use more than the recommended dose or use for longer than prescribed without checking with your doctor.

  • Actemra may lower the ability of your body to fight infection. Avoid contact with people who have colds or infections. Tell your doctor if you notice signs of infection like fever, sore throat, rash, or chills.

  • Serious stomach or bowel problems have been reported with the use of Actemra. The risk may be increased if you have a certain bowel problem (diverticulitis). Tell your doctor if you develop persistent stomach pain, blood in your stool or vomit, fever, or a change in your bowel habits.

  • Actemra may increase the risk of developing cancer. Discuss any questions or concerns with your doctor.

  • Tell your doctor or dentist that you take Actemra before you receive any medical or dental care, emergency care, or surgery.

  • Actemra may reduce the number of clot-forming cells (platelets) in your blood. Avoid activities that may cause bruising or injury. Tell your doctor if you have unusual bruising or bleeding. Tell your doctor if you have dark, tarry, or bloody stools.

  • Before you use Actemra, discuss your vaccination history with your doctor to be sure that you are up to date on vaccinations.

  • Do not receive a live vaccine (eg, measles, mumps) while you are taking Actemra. Talk with your doctor before you receive any vaccine.

  • Hormonal birth control (eg, birth control pills) may not work as well while you are using Actemra. To prevent pregnancy, use an extra form of birth control (eg, condoms).

  • Actemra may interfere with certain lab tests, including tests for TB infection. Be sure your doctor and lab personnel know you are using Actemra.

  • Lab tests, including TB, liver function, cholesterol and lipid levels, and complete blood cell counts, may be performed while you use Actemra. These tests may be used to monitor your condition or check for side effects. Be sure to keep all doctor and lab appointments.

  • Use Actemra with caution in the ELDERLY; they may be more sensitive to its side effects, especially an increased risk of infection.

  • Actemra should be used with extreme caution in CHILDREN younger than 2 years when used for SJIA and in children younger than 18 years when used for other conditions; safety and effectiveness in these children have not been confirmed.

  • PREGNANCY and BREAST-FEEDING: If you become pregnant, contact your doctor. You will need to discuss the benefits and risks of using Actemra while you are pregnant. It is not known if Actemra is found in breast milk. Do not breast-feed while using Actemra.


Possible side effects of Actemra:


All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:



Dizziness; headache.



Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue; unusual hoarseness); bloody, dark, or tarry stools; burning, numbness, or tingling; chest pain; fainting; muscle weakness or aches; numbness, tingling, or pain in the hands or feet; persistent pain, swelling, or redness at the injection site; severe or persistent headache or dizziness; severe or persistent stomach pain; shortness of breath; signs of infection (eg, fever, chills, or persistent sore throat; persistent cough; flu-like symptoms; warm, red, or painful skin or sores; increased or painful urination; severe or persistent diarrhea; unexplained weight loss; blood in the mucus); unusual bruising or bleeding; unusual skin growth or other skin changes; unusual tiredness or weakness; vision changes; vomit that contains blood or looks like coffee grounds.



This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.


See also: Actemra side effects (in more detail)


If OVERDOSE is suspected:


Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately.


Proper storage of Actemra:

Actemra is usually handled and stored by a health care provider. If you are using Actemra at home, store Actemra as directed by your pharmacist or health care provider. Keep Actemra out of the reach of children and away from pets.


General information:


  • If you have any questions about Actemra, please talk with your doctor, pharmacist, or other health care provider.

  • Actemra is to be used only by the patient for whom it is prescribed. Do not share it with other people.

  • If your symptoms do not improve or if they become worse, check with your doctor.

  • Check with your pharmacist about how to dispose of unused medicine.

This information is a summary only. It does not contain all information about Actemra. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.



Issue Date: February 1, 2012

Database Edition 12.1.1.002

Copyright © 2012 Wolters Kluwer Health, Inc.

More Actemra resources


  • Actemra Side Effects (in more detail)
  • Actemra Use in Pregnancy & Breastfeeding
  • Actemra Drug Interactions
  • Actemra Support Group
  • 0 Reviews for Actemra - Add your own review/rating


  • Actemra Prescribing Information (FDA)

  • Actemra Consumer Overview

  • Actemra Monograph (AHFS DI)

  • Actemra Advanced Consumer (Micromedex) - Includes Dosage Information

  • Tocilizumab Professional Patient Advice (Wolters Kluwer)



Compare Actemra with other medications


  • Juvenile Idiopathic Arthritis
  • Rheumatoid Arthritis

Monday, 26 March 2012

loteprednol etabonate and tobramycin Ophthalmic


loe-te-PRED-nol et-a-BOE-nate, toe-bra-MYE-sin


Commonly used brand name(s)

In the U.S.


  • Zylet

Available Dosage Forms:


  • Suspension

Therapeutic Class: Aminoglycoside/Corticosteroid Combination


Pharmacologic Class: Loteprednol


Chemical Class: Aminoglycoside


Uses For loteprednol etabonate and tobramycin


Loteprednol and tobramycin ophthalmic (eye) solution or drops is used to treat inflammation or swelling in the eye that is caused by a bacterial infection.


Loteprednol and tobramycin solution is a combination of a steroid (loteprednol) and an antibiotic (tobramycin). Loteprednol reduces swelling and inflammation. Tobramycin works by killing the bacteria or preventing it from growing.


loteprednol etabonate and tobramycin is available only with your doctor's prescription.


Before Using loteprednol etabonate and tobramycin


In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For loteprednol etabonate and tobramycin, the following should be considered:


Allergies


Tell your doctor if you have ever had any unusual or allergic reaction to loteprednol etabonate and tobramycin or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.


Pediatric


Appropriate studies have not been performed on the relationship of age to the effects of loteprednol and tobramycin eye drops in the pediatric population. Safety and efficacy have not been established.


Geriatric


Appropriate studies performed to date have not demonstrated geriatric-specific problems that would limit the usefulness of loteprednol and tobramycin eye drops in the elderly.


Pregnancy








Pregnancy CategoryExplanation
All TrimestersCAnimal studies have shown an adverse effect and there are no adequate studies in pregnant women OR no animal studies have been conducted and there are no adequate studies in pregnant women.

Breast Feeding


There are no adequate studies in women for determining infant risk when using this medication during breastfeeding. Weigh the potential benefits against the potential risks before taking this medication while breastfeeding.


Interactions with Medicines


Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. Tell your healthcare professional if you are taking any other prescription or nonprescription (over-the-counter [OTC]) medicine.


Interactions with Food/Tobacco/Alcohol


Certain medicines should not be used at or around the time of eating food or eating certain types of food since interactions may occur. Using alcohol or tobacco with certain medicines may also cause interactions to occur. Discuss with your healthcare professional the use of your medicine with food, alcohol, or tobacco.


Other Medical Problems


The presence of other medical problems may affect the use of loteprednol etabonate and tobramycin. Make sure you tell your doctor if you have any other medical problems, especially:


  • Cataract surgery, recent or

  • Cornea (part of the eye) problems, history of or

  • Sclera (part of the eye) problems, history of—May cause side effects to become worse.

  • Fungal (caused by a fungus) eye infection or

  • Herpes simplex eye infection or

  • Smallpox eye infection or

  • Tuberculosis eye infection or

  • Varicella (chickenpox) eye infection or

  • Viral (caused by a virus) eye infection—Should not be used in patients with these conditions.

  • Glaucoma, history of—Use with caution. May make this condition worse.

Proper Use of loteprednol etabonate and tobramycin


Your eye doctor will tell you how much of loteprednol etabonate and tobramycin to use and how often. Do not use more medicine or use it more often than your doctor tells you to. loteprednol etabonate and tobramycin is not for long-term use.


To help clear up your eye infection completely, keep using loteprednol etabonate and tobramycin for the full time of treatment, even if your eye feels better.


If you normally wear soft contact lenses, remove them while you are using loteprednol etabonate and tobramycin. Talk to your eye doctor about this if you have questions.


To use the eye drops:


  • Wash your hands with soap and water.

  • Shake the bottle well before taking the top off and before each dose.

  • For the first dose, make sure the imprinted neckband is on the bottle and holding the top in place.

  • Tilt your head back and, pressing your finger gently on the skin just beneath the lower eyelid, pull the eyelid away from the eye to make a space. Drop the medicine into this space.

  • Let go of the eyelid and gently close the eye. Do not blink. Keep the eye closed for 1 or 2 minutes to allow the medicine to cover the eye.

  • If you think you did not get the drop of medicine into your eye properly, repeat the process with another drop.

  • Wash your hands after using the eye drops to remove any medicine.

  • Never touch the applicator tip to any surface, including the eye, and keep the container tightly closed. This will keep the medicine as germ-free as possible.

Dosing


The dose of loteprednol etabonate and tobramycin will be different for different patients. Follow your doctor's orders or the directions on the label. The following information includes only the average doses of loteprednol etabonate and tobramycin. If your dose is different, do not change it unless your doctor tells you to do so.


The amount of medicine that you take depends on the strength of the medicine. Also, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are using the medicine.


  • For ophthalmic dosage form (eye drops):
    • For eye infections:
      • Adults—Use one or two drops in the affected eye every 4 to 6 hours. Your doctor may tell you to use the drops more often during the first two days for serious infections.

      • Children—Use and dose must be determined by your doctor.



Missed Dose


If you miss a dose of loteprednol etabonate and tobramycin, take it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not double doses.


Storage


Store the medicine in a closed container at room temperature, away from heat, moisture, and direct light. Keep from freezing.


Keep out of the reach of children.


Do not keep outdated medicine or medicine no longer needed.


Ask your healthcare professional how you should dispose of any medicine you do not use.


Precautions While Using loteprednol etabonate and tobramycin


If you will be using loteprednol etabonate and tobramycin for more than a few weeks, your eye doctor will check your eyes at regular visits to make sure it is working properly and is not causing unwanted effects.


If your symptoms do not improve within a few days or if they become worse, check with your eye doctor.


loteprednol etabonate and tobramycin Side Effects


Along with its needed effects, a medicine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.


Check with your doctor immediately if any of the following side effects occur:


More common
  • Blurred vision

  • change in vision

  • feeling like something is in the eye

  • increased intraocular pressure

  • loss of vision

  • pain or irritation of the clear front part of the eye

  • sensitivity of the eyes to light

Less common
  • Blurred vision or seeing blue-green halos around objects

  • decreased vision

  • difficulty seeing at night

  • discharge from the eye

  • dry eyes

  • eyelid burning, redness, itching, pain, or tenderness

  • fast heartbeat

  • fever

  • hives

  • hoarseness

  • irritation and swelling of the eye

  • itching

  • joint pain

  • lid itching and swelling

  • pain in the eye

  • rash

  • redness of the eyelid

  • redness of the skin

  • shortness of breath

  • stiffness or swelling

  • swelling of the eyelids, face, lips, hands, or feet

  • tightness in the chest

  • troubled breathing or swallowing

  • wheezing

Incidence not known
  • Redness of the eye

  • tearing

Some side effects may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:


More common
  • Burning of the eye

  • headache

  • increased sensitivity of the eyes to light

  • stinging of the eye

Other side effects not listed may also occur in some patients. If you notice any other effects, check with your healthcare professional.


Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

See also: loteprednol etabonate and tobramycin Ophthalmic side effects (in more detail)



The information contained in the Thomson Reuters Micromedex products as delivered by Drugs.com is intended as an educational aid only. It is not intended as medical advice for individual conditions or treatment. It is not a substitute for a medical exam, nor does it replace the need for services provided by medical professionals. Talk to your doctor, nurse or pharmacist before taking any prescription or over the counter drugs (including any herbal medicines or supplements) or following any treatment or regimen. Only your doctor, nurse, or pharmacist can provide you with advice on what is safe and effective for you.


The use of the Thomson Reuters Healthcare products is at your sole risk. These products are provided "AS IS" and "as available" for use, without warranties of any kind, either express or implied. Thomson Reuters Healthcare and Drugs.com make no representation or warranty as to the accuracy, reliability, timeliness, usefulness or completeness of any of the information contained in the products. Additionally, THOMSON REUTERS HEALTHCARE MAKES NO REPRESENTATION OR WARRANTIES AS TO THE OPINIONS OR OTHER SERVICE OR DATA YOU MAY ACCESS, DOWNLOAD OR USE AS A RESULT OF USE OF THE THOMSON REUTERS HEALTHCARE PRODUCTS. ALL IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE OR USE ARE HEREBY EXCLUDED. Thomson Reuters Healthcare does not assume any responsibility or risk for your use of the Thomson Reuters Healthcare products.


More loteprednol etabonate and tobramycin Ophthalmic resources


  • Loteprednol etabonate and tobramycin Ophthalmic Side Effects (in more detail)
  • Loteprednol etabonate and tobramycin Ophthalmic Use in Pregnancy & Breastfeeding
  • Loteprednol etabonate and tobramycin Ophthalmic Drug Interactions
  • Loteprednol etabonate and tobramycin Ophthalmic Support Group
  • 4 Reviews for Loteprednol etabonate and tobramycin Ophthalmic - Add your own review/rating


Compare loteprednol etabonate and tobramycin Ophthalmic with other medications


  • Conjunctivitis, Bacterial
  • Cyclitis
  • Iritis
  • Keratitis
  • Uveitis

Diprosalic Ointment





1. Name Of The Medicinal Product



Diprosalic Ointment


2. Qualitative And Quantitative Composition



Betamethasone Dipropionate 0.064% w/w*



(* equivalent to 0.05% Betamethasone)



Salicylic Acid 3.00% w/w



3. Pharmaceutical Form



Ointment



4. Clinical Particulars



4.1 Therapeutic Indications



Betamethasone Dipropionate is a synthetic fluorinated corticosteroid. It is active topically and produces a rapid and sustained response in those inflammatory dermatoses that are normally responsive to topical corticosteroid therapy, and it is also effective in the less responsive conditions, such as psoriasis of the scalp, chronic plaque psoriasis of the hands and feet, but excluding widespread plaque psoriasis.



Topical salicylic acid softens keratin, loosens cornified epithelium and desquamates the epidermis.



Diprosalic presentations are therefore indicated for the treatment of hyperkeratotic and dry corticosteroid-responsive dermatoses where the cornified epithelium may resist penetration of the steroid. The salicylic acid constituent of Diprosalic preparations, as a result of its descaling action, allows access of the dermis more rapidly than by applying steroid alone.



4.2 Posology And Method Of Administration



Adults :



Once to twice daily. In most cases a thin film should be applied to cover the affected area twice daily.



For some patients adequate maintenance therapy may be achieved with less frequent application.



It is recommended that Diprosalic preparations are prescribed for two weeks, and that treatment is reviewed at that time. The maximum weekly dose should not exceed 60g.



Children :



Dosage in children should be limited to 5 days.



4.3 Contraindications



Rosacea, acne, perioral dermatitis, perianal and genital pruritus. Hypersensitivity to any of the ingredients of the Diprosalic presentations contra-indicates their use as does tuberculous and most viral lesions of the skin, particularly herpes simplex, vacinia, varicella. Diprosalic should not be used in napkin eruptions, fungal or bacterial skin infections without suitable concomitant anti-infective therapy.



4.4 Special Warnings And Precautions For Use



Occlusion must not be used, since under these circumstances the keratolytic action of salicylic acid may lead to enhanced absorption of the steroid.



Local and systemic toxicity is common, especially following long continuous use on large areas of damaged skin, in flexures or with polythene occlusion. If used in children or on the face courses should be limited to 5 days. Long term continuous therapy should be avoided in all patients irrespective of age.



Topical corticosteroids may be hazardous in psoriasis for a number of reasons, including rebound relapses following development of tolerance, risk of generalised pustular psoriasis and local systemic toxicity due to impaired barrier function of the skin. Careful patient supervision is important.



It is dangerous if Diprosalic presentations come into contact with the eyes. Avoid contact with the eyes and mucous membranes.



The systemic absorption of betamethasone dipropionate and salicylic acid may be increased if extensive body surface areas or skin folds are treated for prolonged periods or with excessive amounts of steroids. Suitable precautions should be taken in these circumstances, particularly with infants and children.



If irritation or sensitization develops with the use of Diprosalic Ointment and Lotion, treatment should be discontinued.



Any side effects that are reported following systemic use of corticosteroids, including adrenal suppression, may also occur with topical corticosteroids, especially in infants and children.



If excessive dryness or increased skin irritation develops, discontinue use of this preparation.



Peadiatric Use: Peadiatric patients may demonstrate greater susceptibility to topical corticosteroid-induced hypothalamic-pituary-adrenal (HPA) axis suppression and to exogenous corticosteroid effects than mature patients because of greater absorption due to a large skin surface area to body weight ratio.



HPA axis suppression, Cushing's syndrome, linear growth retardation, delayed weight gain, and intracranial hypertension have been reported in children receiving topical corticosteroids. Manifestations of adrenal suppression in children include low plasma cortisol levels and absence of response to ACTH stimulation. Manifestations of intracranial hypertension include a bulging fontanelle, headaches and bilateral papilledema.



4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction



None stated



4.6 Pregnancy And Lactation



Since safety of topical corticosteroid use in pregnant women has not been established, drugs of this class should be used during pregnancy only if the potential benefit justifies the potential risk to the foetus. Drugs of this class should not be used extensively in large amounts or for prolonged periods of time in pregnant patients.



Since it is not known whether topical administration of corticosteroids can result in sufficient systemic absorption to produce detectable quantities in breast milk, a decision should be made to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.



4.7 Effects On Ability To Drive And Use Machines



None stated.



4.8 Undesirable Effects



Diprosalic skin preparations are generally well tolerated and side-effects are rare.



Continuous application without interruption may result in local atrophy of the skin, striae and superficial vascular dilation, particularly on the face.



Adverse reactions that have been reported with the use of topical corticosteroids include: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis and allergic contact dermatitis.



The following may occur more frequently with the use of occlusive dressings: maceration of the skin, secondary infection, skin atrophy, striae and miliaria.



In addition, prolonged use of salicylic acid preparations may cause dermatitis.



4.9 Overdose



Excessive prolonged use of topical corticosteroids can suppress pituitary-adrenal functions resulting in secondary adrenal insufficiency, and produce manifestations of hypercorticism, including Cushing's disease.



Treatment: Appropriate symptomatic treatment is indicated. Acute hypercorticoid symptoms are usually reversible. Treat electrolyte imbalance, if necessary. In case of chronic toxicity, slow withdrawal of corticosteroids is advised.



With topical preparations containing salicylic acid excessive prolonged use may result in symptoms of salicyclism. Treatment is symptomatic. Measures should be taken to rid the body rapidly of salicylate. Adminster oral sodium bicarbonate to alkalinize the urine and force diuresis.



The steroid content of each tube is so low as to have little or no toxic effect in the unlikely event of accidental oral ingestion.



5. Pharmacological Properties



5.1 Pharmacodynamic Properties



Diprosalic preparations contain the dipropionate ester of betamethasone which is a glucocorticoid exhibiting the general properties of corticosteroids, and salicylic acid which has keratolytic properties.



Salicylic acid is applied topically in the treatment of hyperkeratotic and scaling conditions where its keratolytic action facilitates penetration of the corticosteroid.



In pharmacological doses, corticosteroids are used primarily for their anti-inflammatory and/or immune suppressive effects.



Topical corticosteroids such as betamethasone dipropionate are effective in the treatment of a range of dermatoses because of their anti-inflammatory, anti-pruritic and vasoconstrictive actions. However, while the physiologic, pharmacologic and clinical effects of the corticosteroids are well known, the exact mechanisms of their action in each disease are uncertain.



5.2 Pharmacokinetic Properties



Salicylic acid exerts only local action after topical application.



The extent of percutaneous absorption of topical corticosteroids is determined by many factors including vehicle, integrity of the epidermal barrier and the use of occlusive dressings.



Topical corticosteroids can be absorbed through intact, normal skin. Inflammation and/or other disease processes in the skin may increase percutaneous absorption.



Occlusive dressings substantially increase the percutaneous absorption of topical corticosteroids.



Once absorbed through the skin, topical corticosteroids enter pharmacokinetic pathways similar to systemically administered corticosteroids. Corticosteroids are bound to plasma proteins in varying degrees, are metabolised primarily in the liver and excreted by the kidneys. Some of the topical corticosteroids and their metabolites are also excreted in the bile.



5.3 Preclinical Safety Data



There are no pre-clinical data of relevance to the prescriber which are additional to that already included in other sections of the SPC.



6. Pharmaceutical Particulars



6.1 List Of Excipients



Liquid Paraffin



White Soft Paraffin



6.2 Incompatibilities



None Stated.



6.3 Shelf Life



60 months



6.4 Special Precautions For Storage



Do not store above 25°C.



6.5 Nature And Contents Of Container



15, 30 or 100gm expoxy-lined aluminium tubes with plastic caps.



6.6 Special Precautions For Disposal And Other Handling



Not applicable



7. Marketing Authorisation Holder



Schering-Plough Ltd



Shire Park



Welwyn Garden City



Hertfordshire AL7 1TW



England



8. Marketing Authorisation Number(S)



PL 0201/0070



9. Date Of First Authorisation/Renewal Of The Authorisation



10th June 1986 / 25th July 1997



10. Date Of Revision Of The Text



8 June 2009



11. Legal Category


Prescription Only Medicine



Diprosalic-O/UK/06-09/5